Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31333761 | 0.81 | HRH3 (0.41) | MAPK1HRH3MEN1KMT2AGAA | |
| SCHEMBL20511485 | 0.78 | CHRNB2 (0.39) | SMN1; SMN2 | |
| SCHEMBL26738595 | 0.77 | CYP2C19 (0.37) | MAPK1HRH3MEN1KMT2A | |
| SCHEMBL1690170 | 0.76 | HRH3 (0.41) | MAPK1HRH3MEN1KMT2A | |
| SCHEMBL28678042 | 0.75 | HRH3 (0.40) | MAPK1HRH3GAARECQLUSP2 | |
| SCHEMBL3274752 | 0.74 | MAPK1 (0.38) | MAPK1HRH3MEN1KMT2A | |
| SCHEMBL13818241 | 0.74 | MAPK1 (0.38) | MAPK1HRH3MEN1KMT2A | |
| SCHEMBL24751966 | 0.73 | CYP2C19 (0.37) | MAPK1HRH3MEN1KMT2A | |
| SCHEMBL17765394 | 0.73 | MAPK1 (0.37) | MAPK1HRH3MEN1KMT2A | |
| SCHEMBL26118527 | 0.73 | MAPK1 (0.37) | MAPK1HRH3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS, INC. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227471-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | BTK, CBL, XIAP | MAPK1 2171/4885HRH3 3674/4885MEN1 2766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.